Millennium Management’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-17,391
| Closed | -$1.52M | – | 6250 |
|
|
2025
Q4 | $1.52M | Sell |
17,391
-110,169
| -86% | -$9.02M | ﹤0.01% | 4180 |
|
|
2025
Q3 | $8.47M | Buy |
127,560
+112,369
| +740% | +$6.39M | ﹤0.01% | 2561 |
|
|
2025
Q2 | $840K | Sell |
15,191
-119,078
| -89% | -$5.71M | ﹤0.01% | 4537 |
|
|
2025
Q1 | $6.49M | Buy |
+134,269
| New | +$5.63M | ﹤0.01% | 2615 |
|
|
2024
Q3 | – | Sell |
-958,283
| Closed | -$33.2M | – | 6394 |
|
|
2024
Q2 | $33.2M | Buy |
958,283
+915,418
| +2,136% | +$26.8M | 0.02% | 1081 |
|
|
2024
Q1 | $1.24M | Sell |
42,865
-106,298
| -71% | -$2.89M | ﹤0.01% | 4121 |
|
|
2023
Q4 | $3.42M | Buy |
+149,163
| New | +$2.61M | ﹤0.01% | 3130 |
|
|
2023
Q3 | – | Sell |
-351,810
| Closed | -$9.72M | – | 6465 |
|
|
2023
Q2 | $9.72M | Sell |
351,810
-770,532
| -69% | -$19.3M | ﹤0.01% | 2058 |
|
|
2023
Q1 | $25.8M | Sell |
1,122,342
-223,047
| -17% | -$3.75M | 0.01% | 1158 |
|
|
2022
Q4 | $14.7M | Buy |
1,345,389
+1,147,367
| +579% | +$9.68M | 0.01% | 1734 |
|
|
2022
Q3 | $1.67M | Sell |
198,022
-891,506
| -82% | -$8.44M | ﹤0.01% | 3912 |
|
|
2022
Q2 | $8.62M | Buy |
1,089,528
+629,413
| +137% | +$7.61M | 0.01% | 2226 |
|
|
2022
Q1 | $10.9M | Buy |
460,115
+69,042
| +18% | +$1.95M | 0.01% | 2065 |
|
|
2021
Q4 | $13.4M | Sell |
391,073
-131,798
| -25% | -$4.17M | 0.01% | 1832 |
|
|
2021
Q3 | $9.27M | Buy |
522,871
+507,431
| +3,286% | +$21.6M | 0.01% | 2158 |
|
|
2021
Q2 | $693K | Buy |
15,440
+4,548
| +42% | +$150K | ﹤0.01% | 5003 |
|
|
2021
Q1 | $282K | Sell |
10,892
-11,874
| -52% | -$301K | ﹤0.01% | 5254 |
|
|
2020
Q4 | $459K | Buy |
+22,766
| New | +$490K | ﹤0.01% | 4255 |
|
|
2020
Q3 | – | Sell |
-384,205
| Closed | -$6.79M | – | 4746 |
|
|
2020
Q2 | $6.79M | Buy |
384,205
+42,030
| +12% | +$527K | 0.01% | 1507 |
|
|
2020
Q1 | $2.42M | Sell |
342,175
-504,819
| -60% | -$3.78M | 0.01% | 1874 |
|
|
2019
Q4 | $5.97M | Buy |
846,994
+9,102
| +1% | +$90.4K | 0.01% | 1783 |
|
|
2019
Q3 | $10.1M | Buy |
837,892
+26,826
| +3% | +$338K | 0.02% | 1279 |
|
|
2019
Q2 | $9.82M | Sell |
811,066
-82,089
| -9% | -$908K | 0.01% | 1270 |
|
|
2019
Q1 | $11.2M | Buy |
893,155
+203,004
| +29% | +$1.79M | 0.02% | 1163 |
|
|
2018
Q4 | $4.64M | Sell |
690,151
-343,647
| -33% | -$2.73M | 0.01% | 1636 |
|
|
2018
Q3 | $10.6M | Buy |
1,033,798
+805,517
| +353% | +$6.93M | 0.01% | 1276 |
|
|
2018
Q2 | $1.53M | Sell |
228,281
-92,458
| -29% | -$710K | ﹤0.01% | 2579 |
|
|
2018
Q1 | $2.75M | Buy |
320,739
+128,009
| +66% | +$2.41M | ﹤0.01% | 2144 |
|
|
2017
Q4 | $4.01M | Buy |
192,730
+55,378
| +40% | +$982K | 0.01% | 1865 |
|
|
2017
Q3 | $2.43M | Sell |
137,352
-64,360
| -32% | -$891K | ﹤0.01% | 2066 |
|
|
2017
Q2 | $2.28M | Buy |
+201,712
| New | +$2.16M | ﹤0.01% | 2001 |
|
Other funds holding PTGX
FCM
RI
VPM
VCM
JJ
Millennium Management's PTGX Position: Q1 2026 in Review
Millennium Management sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 17,391 shares — an estimated $1.52M sold.
Millennium Management first reported a position in PTGX in Q2 2017 and held it in 31 quarters. The position peaked at $33.2M in Q2 2024. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.
- Millennium Management reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
- Millennium Management sold 17,391 Protagonist Therapeutics shares in Q1 2026, an estimated $1.52M.
- Millennium Management first reported a position in Protagonist Therapeutics in Q2 2017 and held it in 31 quarters.
- Millennium Management's Protagonist Therapeutics position peaked at $33.2M in Q2 2024.
- 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.